ライフサイエンスコーパス: second malignancy

1 rred among 135 patients (12 relapses and two second malignancies).

2 risk of leukemia relapse or development of a second malignancy.

3 ful, but patients have a significant risk of second malignancy.

4 whether the cause is recurrent disease or a second malignancy.

5 er, there is a small but significant risk of second malignancy.

6 and are, therefore, at risk of developing a second malignancy.

7 herapy, recurrence, time since diagnosis, or second malignancy.

8 g in CR for 14, 21, and 71 weeks, all from a second malignancy.

9 lung cancer (NSCLC) are at higher risk of a second malignancy.

10 tive impairment, endocrinopathy, and risk of second malignancy.

11 entire cohort, 9.6% of patients have died of second malignancy.

12 pproaching 21% at 10 years from diagnosis of second malignancy.

13 rker for, the induction of a therapy-induced second malignancy.

14 and who were examined for the induction of a second malignancy.

15 ed with leukemia relapse or development of a second malignancy.

16 potential mechanism for doxorubicin-related second malignancies.

17 apy did not significantly affect the risk of second malignancies.

18 termine whether they had true recurrences or second malignancies.

19 Five other patients died from other second malignancies.

20 eritable predisposition are at high risk for second malignancies.

21 the association between multiple myeloma and second malignancies.

22 llow-up, and limitations of ascertainment of second malignancies.

23 tiologic clues to lymphoma as well as to the second malignancies.

24 s of follow-up, and reporting AML/MDS or all second malignancies.

25 D and was not associated with an increase in second malignancies.

26 There were seven second malignancies.

27 ut also to reduce the risk of development of second malignancies.

28 t of multi-factorial diseases, in particular second malignancies.

29 Forty-seven patients developed 58 second malignancies.

30 incidence ratios showed excess risk for all second malignancies (12; 95% confidence interval [CI], 8

31 -1.6% for Hodgkin's disease, 8.1%+/-2.6% for second malignancy, 4.0%+/-1.8% for cardiac disease, 3.9%

32 ncies differ and whether the occurrence of a second malignancy affects the risk of subsequent maligna

33 to reduce the incidence of radiation-induced second malignancies after a course of definitive radiati

34 w-up demonstrates a significant incidence of second malignancies after ABMT for NHL.

35 The overall risk of second malignancies after Ewing's sarcomas is similar to

36 review discusses current knowledge regarding second malignancies after multiple myeloma and gives fut

37 evious studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) a

38 The excess risk of second malignancy after Hodgkin disease continues to be

39 The excess risk of second malignancy after Hodgkin disease is an increasing

40 e at treatment has a major effect on risk of second malignancy after Hodgkin's disease.

41 mine the prognosis of patients who develop a second malignancy after radiation treatment with or with

42 ith clinical stage I-IV Hodgkin disease, 181 second malignancies and 18 third malignancies were obser

43 cancer treatment, and may raise the risk of second malignancies and comorbidities.

44 a mechanistic paradigm for the induction of second malignancies and drug resistance.

45 ow-up, presents data on failure patterns and second malignancies and explores selected subset analyse

46 er, the leading causes of excess deaths were second malignancies and recurrent disease, followed by i

47 New information relating to the risk of second malignancies and the ability of the myeloid growt

48 sts to advise patients regarding the risk of second malignancies and treatment-related cancers.

49 w-up of 22.6 years, 832 patients developed a second malignancy and 126 patients a third one.

50 mulative incidence rates at 20 years for any second malignancy and for secondary sarcoma were 9.2% (S

51 rough 1993 was assembled and followed-up for second malignancy and mortality.

52 reatment, including the risk of developing a second malignancy and non-neoplastic complications, most

53 e events, including 90 leukemic relapses, 40 second malignancies, and four deaths in remission.

54 ffects like osteoporosis, heart disease, and second malignancies, and promoting healthy lifestyles.

55 Toxicities, including second malignancies, appear acceptable, given the magnit

56 Because second malignancies are associated with high mortality,

57 Second malignancies are responsible for a significant fr

58 ality, locoregional and distant failure, and second malignancies as first events.

59 ribes associations between sporadic GIST and second malignancies, as well as new contributions to our

60 There have been 18 second malignancies associated with ABVD and 28 associat

61 The cumulative risk of developing second malignancies at 10 years was 0.9%, 6.6%, and 6% w

62 The estimated cumulative risk of a second malignancy at 20 years after diagnosis was 1.8% (

63 tients were alive and no patient developed a second malignancy at a median follow up of 25 months.

64 17.2 years) and the cumulative incidence of second malignancy before another first event was 2.7% (9

65 Two patients developed second malignancies, but none have developed myelodyspla

66 uce cardiac complications but did not lessen second malignancies compared with higher doses used hist

67 A second malignancy during the course of follow-up was dia

68 Of 11 second malignancies, eight occurred in patients who rece

69 Of seven patients with second malignancies, five died.

70 maximize survival and minimize the risk for second malignancies for individual patients.

71 free of a second malignancy, patients with a second malignancy had a higher risk of developing subseq

72 An excess risk of second malignancies has been reported in survivors of Ew

73 Five second malignancies have occurred in four patients.

74 hat Hodgkin lymphoma survivors who develop a second malignancy have increased risk of developing yet

75 e of Hodgkin's disease increased the risk of second malignancy (hazards ratio [HR] = 2.6, P < .001).

76 adverse treatment effects (treatment death, second malignancy; HR 0.52, 0.24-1.11, p=0.11).

77 of death resulting from noncancer causes and second malignancies (ie, competing mortality).

78 There seems to be no increased risk of second malignancies in patients undergoing LRT using mod

79 ng to evaluate the possible clonal origin of second malignancies in various cancer types.

80 Second malignancies in women diagnosed with thyroid canc

81 ecurrent primary malignancy in 61% of cases, second malignancy in 20%, nonneoplastic treatment compli

82 Six patients were diagnosed with second malignancies, including four patients who develop

83 ra (P < .0001), while the risk of death from second malignancies increased, although not statisticall

84 with high mortality, prognostic factors for second malignancy influence long-term overall survival.

85 nical studies have shown that development of second malignancies is an uncommon but real risk for cho

86 ing risk found that the 10-year incidence of second malignancy is 21%, with 10.0% non-MDS malignancie

87 The principal risk factor for second malignancy is increased age at ABMT (P = .0002).

88 te consequences such as an increased risk of second malignancy may compromise this approach and close

89 ed as progression, malignant transformation, second malignancy, medical complication, or external cau

90 No patients developed a second malignancy, metastatic disease, renal disease, or

91 ents resulted from Hodgkin's disease (n=36), second malignancies (n=14), infections (n=7), accidents

92 nts, including relapse/progression (n = 35), second malignancy (n = 2), and accidental death (n = 1);

93 use of higher mortality rates resulting from second malignancies observed after treatment with BEACOP

94 Second malignancies occurred in 459 cohort members.

95 Four of the five second malignancies occurred in children younger than 2

96 Three hundred twenty-two second malignancies occurred.

97 No second malignancies occurred.

98 In total, 123 second malignancies occurred.

99 onizing radiation in 12 radiation-associated second malignancies of different tumour types.

100 s not been a markedly increased incidence of second malignancies or late opportunistic infections.

101 red for events, defined as tumor recurrence, second malignancy, or death.

102 Recurrent disease, second malignancy, or late-onset treatment effects in an

103 = 25) or surgery, had a coexistent or prior second malignancy, or who had unresectable or metastatic

104 investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia,

105 Cancer survivors are at greater risk for second malignancies, other comorbidities, and accelerate

106 patients are at elevated risk of developing second malignancy, particularly leukemia and lung cancer

107 Compared with patients still free of a second malignancy, patients with a second malignancy had

108 rs, there was a 2.3% and 4.0% excess risk of second malignancy per person per year.

109 gkin's disease was associated with risk of a second malignancy related to treatment, the literature i

110 phoma subtypes contribute to the patterns of second malignancy risk.

111 Nine died of progressive disease (one second malignancy), six relapsed and are alive with dise

112 ios (RR) were calculated to compare observed second malignancy (SM) rates in this cohort with expecte

113 Late mortality, second malignancy (SMN) rates, health care utilization,

114 thelioma may need to be added to the list of second malignancies that arise following radiation thera

115 h chemotherapy alone leads to raised risk of second malignancy, this risk is lower and affects fewer

116 r survivorship due to many late effects (eg, second malignancies, thyroid disease, cardiovascular dis

117 In HL survivors who had a second malignancy, treating physicians should be aware o

118 a CNS relapse; 16 secondary AML; three other second malignancies; two withdrew for transplant; three

119 The observed-to-expected ratio for second malignancies was 2.03 (95% confidence interval, 1

120 urrent information on relapse of disease and second malignancies was obtained via an institutional re

121 The frequency of second malignancies was similar between the two treatmen

122 he incidence of opportunistic infections and second malignancies was similar in both groups.

123 The cumulative incidence of any second malignancy was 10.6% at 20 years, increasing to 2

124 Duration from diagnosis of initial tumor to second malignancy was 33, 35, 57, 66, and 92 months.

125 The 5-year survival after development of a second malignancy was 38.1%, with the worst prognosis se

126 The risk of a second malignancy was 4.7-fold increased (95% confidence

127 ion; the risk for a third malignancy after a second malignancy was 5.4-fold (95% CI, 4.4-6.5) increas

128 The relative risk (RR) of developing a second malignancy was 5.6.

129 per 10,000 person-years (AR) of developing a second malignancy was 69.6 (7.0% excess risk per person

130 Time to second malignancy was 7 years 8 months, 4 years 9 months

131 The median latency to the diagnosis of the second malignancy was 7.6 years (range, 3.5 to 25.7).

132 estigation were observed, and occurrences of second malignancy was compared with expectations based o

133 Their risk of leukemia relapse or second malignancy was compared with that of survivors wh

134 The 15-year risk of any second malignancy was nearly identical for both cohorts

135 Survival following development of a second malignancy was poor in patients with leukemia, ga

136 The median interval to diagnosis of a second malignancy was shortest for leukemia, 4.3 years,

137 tuarial risks, and absolute excess risks for second malignancies were calculated.

138 Cumulative incidence rates of second malignancies were calculated.

139 Second malignancies were categorized as contralateral br

140 and cumulative radiation dose to the risk of second malignancies were evaluated.

141 None of the second malignancies were non-Hodgkin's lymphoma (NHL).

142 Second malignancies were observed in 18 MPT-T patients v

143 Second malignancies were observed in 21 patients with ra

144 Nine second malignancies were observed with thalidomide-predn

145 Overall, 23 second malignancies were registered during follow-up: fo

146 relapses involved the bone marrow, and three second malignancies were reported.

147 Overall, 13 second malignancies were reported: one in the ABVD arm a

148 Second malignancies were significantly more frequent in

149 Fertility was not greatly impaired, and second malignancies were uncommon.

150 lative risk (RR) and absolute excess risk of second malignancy were 4.6 and 89.3/10 000 person-years.

151 ange, 3.0 to 30), 16 patients have developed second malignancies, which included 10 sarcomas (five os

152 Second malignancies, which might be attributed to treatm

153 ot associated with a significant increase in second malignancies with this doxorubicin-containing che

154 Five of the 198 children developed second malignancies, with a cumulative risk at 8 years o